Mesoblast's Ryoncil generates US$115M in fiscal 2026 as it refinances with US$125M loan
The Australian cell therapy company reports a year of full US selling, 98% payer coverage and a cheaper debt package, with late-stage readouts pencilled in for 2027.
Mesoblast reported US$115M in net revenue from Ryoncil for its 2026 financial year, the first twelve-month period in which the product was sold in the US. The figure comes from the company's full-year investor presentation and has not been independently verified. Mesoblast describes Ryoncil as the sole mesenchymal stromal cell therapy cleared by the US Food and Drug Administration.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Mesoblast Ltd ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.